赛诺菲和再生元公司报告了针对IL-33通路的COPD药物的混合三期试验结果Sanofi and Regeneron Report Mixed Phase 3 Results for COPD Drug Targeting IL-33 Pathway

动脉网2025-05-30

by Mark Chiang马克·蒋Share To分享到Sanofi and Regeneron have released findings from two Phase 3 clinical trials evaluating their experimental drug, itepekimab, for chronic obstructive pulmonary disease (...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2539221846?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-30 19:09","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2539221846","market":"us","top_or_hot":-1,"title":"赛诺菲和再生元公司报告了针对IL-33通路的COPD药物的混合三期试验结果Sanofi and Regeneron Report Mixed Phase 3 Results for COPD Drug Targeting IL-33 Pathway","media":"动脉网","content":"<div>\n<p>by Mark Chiang马克·蒋Share To分享到Sanofi and Regeneron have released findings from two Phase 3 clinical trials evaluating their experimental drug, itepekimab, for chronic obstructive pulmonary disease (...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530191327950828f6&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>赛诺菲和再生元公司报告了针对IL-33通路的COPD药物的混合三期试验结果Sanofi and Regeneron Report Mixed Phase 3 Results for COPD Drug Targeting IL-33 Pathway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n赛诺菲和再生元公司报告了针对IL-33通路的COPD药物的混合三期试验结果Sanofi and Regeneron Report Mixed Phase 3 Results for COPD Drug Targeting IL-33 Pathway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-30 19:09 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530191327950828f6&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>by Mark Chiang马克·蒋Share To分享到Sanofi and Regeneron have released findings from two Phase 3 clinical trials evaluating their experimental drug, itepekimab, for chronic obstructive pulmonary disease (...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530191327950828f6&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNYNF","symbol_name":"Sanofi","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530191327950828f6&s=b","article_id":"2539221846","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530191327950828f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2539221846","pubTimestamp":1748603340,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"Following the announcement, both companies experienced a decline in their stock prices..公告发布后，两家公司的股价均出现下跌。The studies assessed itepekimab’s efficacy in reducing exacerbations among COPD patients who were former smokers. While the drug showed potential in lowering flare-ups compared to standard treatments, it did not achieve statistically significant improvements across all primary endpoints. The trials aimed to explore whether targeting interleukin-33 , an inflammatory pathway linked to COPD progression, could offer new therapeutic benefits.这些研究评估了伊替普单抗在减少曾吸烟的慢性阻塞性肺病患者急性加重方面的疗效。试验旨在探索针对白细胞介素-33这一与COPD进展相关的炎症通路，是否能提供新的治疗益处。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SNYNF":"Sanofi","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4007":"制药","LU0882574055.USD":"富达全球健康医疗A ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","REGN":"再生元制药公司","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","GCVRZ":"Sanofi","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","SNY":"赛诺菲安万特","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","BK4588":"碎股"},"translate_title":"Sanofi and Regeneron report results from hybrid phase III trial of COPD drugs targeting the IL-33 pathway Sanofi and Regeneron Report Mixed Phase 3 Results for COPD Drug Targeting IL-33 Pathway","themeId":"b3a9ed5a6b4b1af59b0d713f5210f4fb","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":0.9,"SNYNF":1,"REGN":0.9,"GCVRZ":1},"content_text":"by Mark Chiang马克·蒋Share To分享到Sanofi and Regeneron have released findings from two Phase 3 clinical trials evaluating their experimental drug, itepekimab, for chronic obstructive pulmonary disease (COPD). The results showed a mixed outcome, with the drug demonstrating some positive effects but failing to meet certain key benchmarks.赛诺菲和再生元公司发布了两项评估其试验性药物伊替匹单抗（itepekimab）用于慢性阻塞性肺疾病（COPD）的III期临床试验结果。结果显示，该药物的结果好坏参半，虽然表现出一些积极效果，但未能达到某些关键指标。Following the announcement, both companies experienced a decline in their stock prices..公告发布后，两家公司的股价均出现下跌。The studies assessed itepekimab’s efficacy in reducing exacerbations among COPD patients who were former smokers. While the drug showed potential in lowering flare-ups compared to standard treatments, it did not achieve statistically significant improvements across all primary endpoints. The trials aimed to explore whether targeting interleukin-33 (IL-33), an inflammatory pathway linked to COPD progression, could offer new therapeutic benefits.这些研究评估了伊替普单抗在减少曾吸烟的慢性阻塞性肺病（COPD）患者急性加重方面的疗效。尽管该药物在降低病情恶化方面相比标准治疗显示出潜力，但在所有主要终点上未达到统计学显著改善。试验旨在探索针对白细胞介素-33（IL-33）这一与COPD进展相关的炎症通路，是否能提供新的治疗益处。Sanofi and Regeneron are continuing to analyze the data as they evaluate next steps for the development of itepekimab..赛诺菲和再生元将继续分析数据，以评估下一步如何开发伊替匹单抗。Newsflash | Powered by GeneOnline AI新闻快讯 | 由GeneOnline AI驱动Source: GO-AI-ne1来源：GO-AI-ne1Date: May 30, 2025日期：2025年5月30日Related posts:相关文章:DrugPatentWatch Article Details Methods for Identifying Factors Influencing Drug Pricing and Revenue GrowthDrugPatentWatch 文章详细介绍了识别影响药品定价和收入增长因素的方法Drug Patent Watch: Strategies to Manage Costs of Litigation by Thorough Patent Landscaping.药品专利观察：通过全面的专利布局管理诉讼成本的策略。FDA Approves Bristol Myers Squibb’s Opdivo and Yervoy Combination ImmunotherapyFDA批准百时美施贵宝的Opdivo和Yervoy联合免疫疗法Drug Patent Watch Strategy Includes Patent Mapping to Inform Business Decisions药物专利观察战略包括专利图谱以指导商业决策©www.geneonline.com All rights reserved. Collaborate with us:©www.geneonline.com 版权所有。与我们合作：[email protected]电子邮件地址Author作者Mark Chiang蒋志光Related Post相关内容News Flash新闻快讯High-Speed Tablet Presses Become Essential for Meeting Pharmaceutical and Nutraceutical Production Standards高速平板压片机已成为满足制药和营养品生产标准的必备设备2025-05-302025年5月30日","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2539221846","isCrawlerRequest":true}